Sandra Croockewit - Concepedia

Author

Sandra Croockewit

Also Known As

S Croockewit, S. Croockewit, Sandra A. Croockewit, Sandra A. J. Croockewit, Sandra A.J. Croockewit, Sandra AJ Croockewit, Sandra Croockewit, Sandra J. Croockewit

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center University Medical Center Utrecht Erasmus MC Cancer Institute University Medical Center Groningen

About

Sandra Croockewit is an author at Radboud University Nijmegen specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	725
2	Immunology	5	5	528
3	Health Sciences	1	1	197
4	Cell Biology	1	1	28
5	Marrow Transplantation	1	1	32

Sandra Croockewit

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses Julien Haroche, Frédéric Charlotte, Laurent Arnaud, Blood	2012	682
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients Jurjen Tel, Erik H.J.G. Aarntzen, Tetsuro Baba, Cancer Research ImmunologyPathologyCd4 T Cell ResponsesDermatologyImmunotherapy	2013	342
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. I. Jolanda M. de Vries, W. Joost Lesterhuis, Nicole M. Scharenborg, PubMed	2003	329
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman, Blood	2009	275
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells Gerty Schreibelt, Kalijn F. Bol, Harm Westdorp, Clinical Cancer Research	2015	231
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial Hartmut Goldschmidt, H M Lokhorst, E K, Leukemia Hematological MalignancyOncologyHematologyMyeloid NeoplasiaHigh-dose Therapy	2017	197
Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients W. Joost Lesterhuis, I. Jolanda M. de Vries, Gerty Schreibelt, Clinical Cancer Research	2011	187
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld, Haematologica	2007	142
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial Christoph Scheid, P. Sonneveld, Ingo Schmidt‐Wolf, Haematologica	2013	126
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt, Blood	2010	88

Page 1